nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—CYP1A1—kidney cancer	0.194	0.653	CbGaD
Dapagliflozin—ABCB1—kidney cancer	0.103	0.347	CbGaD
Dapagliflozin—UGT1A9—Sorafenib—kidney cancer	0.0444	0.122	CbGbCtD
Dapagliflozin—ABCB1—Temsirolimus—kidney cancer	0.0236	0.0647	CbGbCtD
Dapagliflozin—CYP1A1—Erlotinib—kidney cancer	0.0227	0.0621	CbGbCtD
Dapagliflozin—CYP2D6—Temsirolimus—kidney cancer	0.0223	0.061	CbGbCtD
Dapagliflozin—CYP3A4—Everolimus—kidney cancer	0.021	0.0574	CbGbCtD
Dapagliflozin—SLC5A4—nephron—kidney cancer	0.0162	0.172	CbGeAlD
Dapagliflozin—CYP1A2—Pazopanib—kidney cancer	0.0142	0.0389	CbGbCtD
Dapagliflozin—CYP3A4—Temsirolimus—kidney cancer	0.0142	0.0388	CbGbCtD
Dapagliflozin—CYP2C9—Capecitabine—kidney cancer	0.0133	0.0365	CbGbCtD
Dapagliflozin—SLC5A4—urine—kidney cancer	0.013	0.138	CbGeAlD
Dapagliflozin—ABCB1—Pazopanib—kidney cancer	0.0124	0.034	CbGbCtD
Dapagliflozin—SLC5A2—nephron—kidney cancer	0.0123	0.13	CbGeAlD
Dapagliflozin—CYP2D6—Pazopanib—kidney cancer	0.0117	0.032	CbGbCtD
Dapagliflozin—ABCB1—Dactinomycin—kidney cancer	0.0114	0.0311	CbGbCtD
Dapagliflozin—CYP1A2—Erlotinib—kidney cancer	0.0101	0.0277	CbGbCtD
Dapagliflozin—SLC5A2—urine—kidney cancer	0.00986	0.104	CbGeAlD
Dapagliflozin—ABCB1—Gemcitabine—kidney cancer	0.00898	0.0246	CbGbCtD
Dapagliflozin—ABCB1—Erlotinib—kidney cancer	0.00886	0.0243	CbGbCtD
Dapagliflozin—CYP2C9—Paclitaxel—kidney cancer	0.00836	0.0229	CbGbCtD
Dapagliflozin—CYP2D6—Erlotinib—kidney cancer	0.00835	0.0229	CbGbCtD
Dapagliflozin—CYP1A2—Sorafenib—kidney cancer	0.00824	0.0226	CbGbCtD
Dapagliflozin—ABCB1—Paclitaxel—kidney cancer	0.00811	0.0222	CbGbCtD
Dapagliflozin—CYP3A4—Pazopanib—kidney cancer	0.00744	0.0204	CbGbCtD
Dapagliflozin—CYP2C9—Sorafenib—kidney cancer	0.00742	0.0203	CbGbCtD
Dapagliflozin—ABCB1—Sorafenib—kidney cancer	0.0072	0.0197	CbGbCtD
Dapagliflozin—ABCB1—Vinblastine—kidney cancer	0.00711	0.0195	CbGbCtD
Dapagliflozin—ABCB1—Vincristine—kidney cancer	0.00699	0.0191	CbGbCtD
Dapagliflozin—CYP2D6—Sorafenib—kidney cancer	0.00679	0.0186	CbGbCtD
Dapagliflozin—CYP2D6—Vinblastine—kidney cancer	0.0067	0.0184	CbGbCtD
Dapagliflozin—ABCB1—Sunitinib—kidney cancer	0.00584	0.016	CbGbCtD
Dapagliflozin—CYP3A4—Erlotinib—kidney cancer	0.00531	0.0145	CbGbCtD
Dapagliflozin—CYP3A4—Paclitaxel—kidney cancer	0.00486	0.0133	CbGbCtD
Dapagliflozin—ABCB1—Doxorubicin—kidney cancer	0.00437	0.012	CbGbCtD
Dapagliflozin—CYP3A4—Sorafenib—kidney cancer	0.00432	0.0118	CbGbCtD
Dapagliflozin—CYP3A4—Vinblastine—kidney cancer	0.00426	0.0117	CbGbCtD
Dapagliflozin—CYP3A4—Vincristine—kidney cancer	0.00419	0.0115	CbGbCtD
Dapagliflozin—CYP2D6—Doxorubicin—kidney cancer	0.00412	0.0113	CbGbCtD
Dapagliflozin—SLC5A4—nephron tubule—kidney cancer	0.0035	0.0371	CbGeAlD
Dapagliflozin—CYP3A4—Sunitinib—kidney cancer	0.0035	0.00958	CbGbCtD
Dapagliflozin—SLC5A4—renal system—kidney cancer	0.00318	0.0337	CbGeAlD
Dapagliflozin—SLC5A4—kidney—kidney cancer	0.00308	0.0326	CbGeAlD
Dapagliflozin—SLC5A11—cortex of kidney—kidney cancer	0.00272	0.0288	CbGeAlD
Dapagliflozin—SLC5A2—nephron tubule—kidney cancer	0.00265	0.0281	CbGeAlD
Dapagliflozin—CYP3A4—Doxorubicin—kidney cancer	0.00262	0.00717	CbGbCtD
Dapagliflozin—SLC5A2—renal system—kidney cancer	0.00241	0.0255	CbGeAlD
Dapagliflozin—SLC5A2—kidney—kidney cancer	0.00233	0.0247	CbGeAlD
Dapagliflozin—SLC5A2—cortex of kidney—kidney cancer	0.00227	0.0241	CbGeAlD
Dapagliflozin—SLC5A1—nephron tubule—kidney cancer	0.00201	0.0213	CbGeAlD
Dapagliflozin—SLC5A1—renal system—kidney cancer	0.00183	0.0194	CbGeAlD
Dapagliflozin—SLC5A1—kidney—kidney cancer	0.00177	0.0187	CbGeAlD
Dapagliflozin—SLC5A1—cardiac atrium—kidney cancer	0.00164	0.0173	CbGeAlD
Dapagliflozin—UGT2B4—cardiac atrium—kidney cancer	0.00151	0.016	CbGeAlD
Dapagliflozin—CYP1A2—urine—kidney cancer	0.00143	0.0151	CbGeAlD
Dapagliflozin—CYP2C9—urine—kidney cancer	0.00135	0.0143	CbGeAlD
Dapagliflozin—UGT1A9—renal system—kidney cancer	0.00115	0.0122	CbGeAlD
Dapagliflozin—UGT1A9—kidney—kidney cancer	0.00111	0.0118	CbGeAlD
Dapagliflozin—CYP3A4—urine—kidney cancer	0.00103	0.0109	CbGeAlD
Dapagliflozin—CYP2D6—urine—kidney cancer	0.00102	0.0108	CbGeAlD
Dapagliflozin—UGT2B7—renal system—kidney cancer	0.000927	0.00982	CbGeAlD
Dapagliflozin—Canagliflozin—ABCB1—kidney cancer	0.000926	1	CrCbGaD
Dapagliflozin—UGT2B7—kidney—kidney cancer	0.000896	0.0095	CbGeAlD
Dapagliflozin—CYP1A2—renal system—kidney cancer	0.000349	0.0037	CbGeAlD
Dapagliflozin—CYP1A1—renal system—kidney cancer	0.000344	0.00365	CbGeAlD
Dapagliflozin—CYP1A1—kidney—kidney cancer	0.000333	0.00353	CbGeAlD
Dapagliflozin—CYP1A1—cardiac atrium—kidney cancer	0.000308	0.00327	CbGeAlD
Dapagliflozin—CYP3A4—renal system—kidney cancer	0.000253	0.00268	CbGeAlD
Dapagliflozin—CYP2D6—renal system—kidney cancer	0.000249	0.00263	CbGeAlD
Dapagliflozin—CYP3A4—kidney—kidney cancer	0.000244	0.00259	CbGeAlD
Dapagliflozin—CYP2D6—kidney—kidney cancer	0.00024	0.00255	CbGeAlD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.000211	0.00164	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Gemcitabine—kidney cancer	0.000211	0.00164	CcSEcCtD
Dapagliflozin—Discomfort—Vinblastine—kidney cancer	0.000211	0.00164	CcSEcCtD
Dapagliflozin—Renal failure—Gemcitabine—kidney cancer	0.00021	0.00164	CcSEcCtD
Dapagliflozin—Discomfort—Everolimus—kidney cancer	0.00021	0.00164	CcSEcCtD
Dapagliflozin—Myocardial infarction—Gemcitabine—kidney cancer	0.00021	0.00163	CcSEcCtD
Dapagliflozin—Malnutrition—Sunitinib—kidney cancer	0.000208	0.00162	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Paclitaxel—kidney cancer	0.000208	0.00162	CcSEcCtD
Dapagliflozin—Oedema—Everolimus—kidney cancer	0.000204	0.00159	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.000204	0.00159	CcSEcCtD
Dapagliflozin—Infection—Everolimus—kidney cancer	0.000202	0.00158	CcSEcCtD
Dapagliflozin—Hypersensitivity—Temsirolimus—kidney cancer	0.000202	0.00157	CcSEcCtD
Dapagliflozin—Back pain—Sunitinib—kidney cancer	0.000202	0.00157	CcSEcCtD
Dapagliflozin—Influenza—Paclitaxel—kidney cancer	0.000201	0.00157	CcSEcCtD
Dapagliflozin—Thirst—Capecitabine—kidney cancer	0.000201	0.00156	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Vincristine—kidney cancer	0.0002	0.00156	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Vincristine—kidney cancer	0.000199	0.00155	CcSEcCtD
Dapagliflozin—Urethral disorder—Vincristine—kidney cancer	0.000199	0.00155	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Doxorubicin—kidney cancer	0.000198	0.00155	CcSEcCtD
Dapagliflozin—Angioedema—Sorafenib—kidney cancer	0.000198	0.00154	CcSEcCtD
Dapagliflozin—Skin disorder—Everolimus—kidney cancer	0.000198	0.00154	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Everolimus—kidney cancer	0.000197	0.00153	CcSEcCtD
Dapagliflozin—ABCB1—nephron tubule—kidney cancer	0.000197	0.00208	CbGeAlD
Dapagliflozin—Oedema—Erlotinib—kidney cancer	0.000197	0.00153	CcSEcCtD
Dapagliflozin—Infection—Erlotinib—kidney cancer	0.000195	0.00152	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Capecitabine—kidney cancer	0.000195	0.00152	CcSEcCtD
Dapagliflozin—Extravasation—Doxorubicin—kidney cancer	0.000194	0.00151	CcSEcCtD
Dapagliflozin—Hyponatraemia—Capecitabine—kidney cancer	0.000192	0.00149	CcSEcCtD
Dapagliflozin—Skin disorder—Erlotinib—kidney cancer	0.000191	0.00149	CcSEcCtD
Dapagliflozin—Pain in extremity—Capecitabine—kidney cancer	0.000191	0.00149	CcSEcCtD
Dapagliflozin—Angioedema—Sunitinib—kidney cancer	0.00019	0.00148	CcSEcCtD
Dapagliflozin—Hypotension—Everolimus—kidney cancer	0.00019	0.00148	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Gemcitabine—kidney cancer	0.00019	0.00148	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Gemcitabine—kidney cancer	0.000189	0.00147	CcSEcCtD
Dapagliflozin—Urethral disorder—Gemcitabine—kidney cancer	0.000188	0.00147	CcSEcCtD
Dapagliflozin—Dysuria—Paclitaxel—kidney cancer	0.000188	0.00146	CcSEcCtD
Dapagliflozin—Hypertension—Sorafenib—kidney cancer	0.000187	0.00146	CcSEcCtD
Dapagliflozin—Pollakiuria—Paclitaxel—kidney cancer	0.000186	0.00145	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.000183	0.00143	CcSEcCtD
Dapagliflozin—Nocturia—Doxorubicin—kidney cancer	0.000183	0.00142	CcSEcCtD
Dapagliflozin—Dizziness—Temsirolimus—kidney cancer	0.000181	0.00141	CcSEcCtD
Dapagliflozin—Hypertension—Sunitinib—kidney cancer	0.00018	0.0014	CcSEcCtD
Dapagliflozin—Infestation—Paclitaxel—kidney cancer	0.000179	0.0014	CcSEcCtD
Dapagliflozin—Infestation NOS—Paclitaxel—kidney cancer	0.000179	0.0014	CcSEcCtD
Dapagliflozin—ABCB1—renal system—kidney cancer	0.000179	0.00189	CbGeAlD
Dapagliflozin—Blood creatinine increased—Capecitabine—kidney cancer	0.000179	0.00139	CcSEcCtD
Dapagliflozin—Dehydration—Capecitabine—kidney cancer	0.000177	0.00138	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Sorafenib—kidney cancer	0.000177	0.00138	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Paclitaxel—kidney cancer	0.000177	0.00138	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000176	0.00137	CcSEcCtD
Dapagliflozin—Renal failure—Paclitaxel—kidney cancer	0.000176	0.00137	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Everolimus—kidney cancer	0.000176	0.00137	CcSEcCtD
Dapagliflozin—Myocardial infarction—Paclitaxel—kidney cancer	0.000176	0.00137	CcSEcCtD
Dapagliflozin—Infection—Sorafenib—kidney cancer	0.000176	0.00137	CcSEcCtD
Dapagliflozin—Constipation—Vinblastine—kidney cancer	0.000175	0.00136	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Capecitabine—kidney cancer	0.000174	0.00136	CcSEcCtD
Dapagliflozin—Urinary tract infection—Paclitaxel—kidney cancer	0.000174	0.00136	CcSEcCtD
Dapagliflozin—Constipation—Everolimus—kidney cancer	0.000174	0.00136	CcSEcCtD
Dapagliflozin—ABCB1—kidney—kidney cancer	0.000173	0.00183	CbGeAlD
Dapagliflozin—Rash—Temsirolimus—kidney cancer	0.000173	0.00134	CcSEcCtD
Dapagliflozin—Dermatitis—Temsirolimus—kidney cancer	0.000172	0.00134	CcSEcCtD
Dapagliflozin—Skin disorder—Sorafenib—kidney cancer	0.000172	0.00134	CcSEcCtD
Dapagliflozin—Headache—Temsirolimus—kidney cancer	0.000172	0.00134	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Capecitabine—kidney cancer	0.000171	0.00133	CcSEcCtD
Dapagliflozin—Dizziness—Pazopanib—kidney cancer	0.000171	0.00133	CcSEcCtD
Dapagliflozin—Back pain—Vincristine—kidney cancer	0.000171	0.00133	CcSEcCtD
Dapagliflozin—Oedema—Sunitinib—kidney cancer	0.00017	0.00133	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Erlotinib—kidney cancer	0.00017	0.00132	CcSEcCtD
Dapagliflozin—Infection—Sunitinib—kidney cancer	0.000169	0.00132	CcSEcCtD
Dapagliflozin—ABCB1—cortex of kidney—kidney cancer	0.000168	0.00178	CbGeAlD
Dapagliflozin—Constipation—Erlotinib—kidney cancer	0.000168	0.00131	CcSEcCtD
Dapagliflozin—Discomfort—Dactinomycin—kidney cancer	0.000166	0.00129	CcSEcCtD
Dapagliflozin—Skin disorder—Sunitinib—kidney cancer	0.000165	0.00129	CcSEcCtD
Dapagliflozin—Influenza—Capecitabine—kidney cancer	0.000165	0.00128	CcSEcCtD
Dapagliflozin—Rash—Pazopanib—kidney cancer	0.000163	0.00127	CcSEcCtD
Dapagliflozin—Nausea—Temsirolimus—kidney cancer	0.000163	0.00127	CcSEcCtD
Dapagliflozin—Dermatitis—Pazopanib—kidney cancer	0.000162	0.00127	CcSEcCtD
Dapagliflozin—Back pain—Gemcitabine—kidney cancer	0.000162	0.00126	CcSEcCtD
Dapagliflozin—Headache—Pazopanib—kidney cancer	0.000162	0.00126	CcSEcCtD
Dapagliflozin—Oedema—Dactinomycin—kidney cancer	0.000161	0.00125	CcSEcCtD
Dapagliflozin—Body temperature increased—Everolimus—kidney cancer	0.000161	0.00125	CcSEcCtD
Dapagliflozin—Angina pectoris—Capecitabine—kidney cancer	0.000161	0.00125	CcSEcCtD
Dapagliflozin—ABCB1—gonad—kidney cancer	0.00016	0.0017	CbGeAlD
Dapagliflozin—Infection—Dactinomycin—kidney cancer	0.00016	0.00125	CcSEcCtD
Dapagliflozin—Vaginal infection—Doxorubicin—kidney cancer	0.00016	0.00125	CcSEcCtD
Dapagliflozin—Blood urea increased—Doxorubicin—kidney cancer	0.00016	0.00125	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Paclitaxel—kidney cancer	0.000159	0.00124	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Paclitaxel—kidney cancer	0.000158	0.00123	CcSEcCtD
Dapagliflozin—Urethral disorder—Paclitaxel—kidney cancer	0.000158	0.00123	CcSEcCtD
Dapagliflozin—Body temperature increased—Erlotinib—kidney cancer	0.000155	0.00121	CcSEcCtD
Dapagliflozin—Dysuria—Capecitabine—kidney cancer	0.000154	0.0012	CcSEcCtD
Dapagliflozin—Nausea—Pazopanib—kidney cancer	0.000153	0.00119	CcSEcCtD
Dapagliflozin—Neoplasm—Doxorubicin—kidney cancer	0.000153	0.00119	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000153	0.00119	CcSEcCtD
Dapagliflozin—Hypertension—Vincristine—kidney cancer	0.000152	0.00119	CcSEcCtD
Dapagliflozin—Constipation—Sorafenib—kidney cancer	0.000151	0.00118	CcSEcCtD
Dapagliflozin—Hypersensitivity—Vinblastine—kidney cancer	0.000151	0.00117	CcSEcCtD
Dapagliflozin—Hypersensitivity—Everolimus—kidney cancer	0.00015	0.00117	CcSEcCtD
Dapagliflozin—Infestation NOS—Capecitabine—kidney cancer	0.000147	0.00115	CcSEcCtD
Dapagliflozin—Infestation—Capecitabine—kidney cancer	0.000147	0.00115	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000147	0.00114	CcSEcCtD
Dapagliflozin—Constipation—Sunitinib—kidney cancer	0.000145	0.00113	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Capecitabine—kidney cancer	0.000145	0.00113	CcSEcCtD
Dapagliflozin—Renal failure—Capecitabine—kidney cancer	0.000145	0.00113	CcSEcCtD
Dapagliflozin—Hypertension—Gemcitabine—kidney cancer	0.000144	0.00112	CcSEcCtD
Dapagliflozin—Myocardial infarction—Capecitabine—kidney cancer	0.000144	0.00112	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Vincristine—kidney cancer	0.000144	0.00112	CcSEcCtD
Dapagliflozin—Oedema—Vincristine—kidney cancer	0.000144	0.00112	CcSEcCtD
Dapagliflozin—Infection—Vincristine—kidney cancer	0.000143	0.00111	CcSEcCtD
Dapagliflozin—Urinary tract infection—Capecitabine—kidney cancer	0.000143	0.00111	CcSEcCtD
Dapagliflozin—Phlebitis—Doxorubicin—kidney cancer	0.000143	0.00111	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Doxorubicin—kidney cancer	0.000141	0.0011	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000141	0.0011	CcSEcCtD
Dapagliflozin—Discomfort—Gemcitabine—kidney cancer	0.000141	0.0011	CcSEcCtD
Dapagliflozin—Urticaria—Sorafenib—kidney cancer	0.00014	0.00109	CcSEcCtD
Dapagliflozin—Malnutrition—Paclitaxel—kidney cancer	0.00014	0.00109	CcSEcCtD
Dapagliflozin—Body temperature increased—Sorafenib—kidney cancer	0.00014	0.00109	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Vincristine—kidney cancer	0.000139	0.00108	CcSEcCtD
Dapagliflozin—Oedema—Gemcitabine—kidney cancer	0.000136	0.00106	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Gemcitabine—kidney cancer	0.000136	0.00106	CcSEcCtD
Dapagliflozin—Infection—Gemcitabine—kidney cancer	0.000136	0.00106	CcSEcCtD
Dapagliflozin—Back pain—Paclitaxel—kidney cancer	0.000135	0.00106	CcSEcCtD
Dapagliflozin—Dizziness—Vinblastine—kidney cancer	0.000135	0.00105	CcSEcCtD
Dapagliflozin—Dizziness—Everolimus—kidney cancer	0.000135	0.00105	CcSEcCtD
Dapagliflozin—Body temperature increased—Sunitinib—kidney cancer	0.000134	0.00105	CcSEcCtD
Dapagliflozin—Hypotension—Vincristine—kidney cancer	0.000134	0.00105	CcSEcCtD
Dapagliflozin—Skin disorder—Gemcitabine—kidney cancer	0.000133	0.00103	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Gemcitabine—kidney cancer	0.000132	0.00103	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Capecitabine—kidney cancer	0.00013	0.00102	CcSEcCtD
Dapagliflozin—Hypersensitivity—Sorafenib—kidney cancer	0.00013	0.00101	CcSEcCtD
Dapagliflozin—Dizziness—Erlotinib—kidney cancer	0.00013	0.00101	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Capecitabine—kidney cancer	0.00013	0.00101	CcSEcCtD
Dapagliflozin—Urethral disorder—Capecitabine—kidney cancer	0.000129	0.00101	CcSEcCtD
Dapagliflozin—Rash—Everolimus—kidney cancer	0.000128	0.001	CcSEcCtD
Dapagliflozin—Dermatitis—Everolimus—kidney cancer	0.000128	0.000999	CcSEcCtD
Dapagliflozin—Headache—Vinblastine—kidney cancer	0.000128	0.000998	CcSEcCtD
Dapagliflozin—Angioedema—Paclitaxel—kidney cancer	0.000128	0.000997	CcSEcCtD
Dapagliflozin—Headache—Everolimus—kidney cancer	0.000128	0.000994	CcSEcCtD
Dapagliflozin—Hypotension—Gemcitabine—kidney cancer	0.000128	0.000994	CcSEcCtD
Dapagliflozin—Body temperature increased—Dactinomycin—kidney cancer	0.000127	0.000992	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Doxorubicin—kidney cancer	0.000126	0.000982	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Doxorubicin—kidney cancer	0.000126	0.000978	CcSEcCtD
Dapagliflozin—Hypersensitivity—Sunitinib—kidney cancer	0.000125	0.000976	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Vincristine—kidney cancer	0.000124	0.000968	CcSEcCtD
Dapagliflozin—Rash—Erlotinib—kidney cancer	0.000124	0.000965	CcSEcCtD
Dapagliflozin—Dermatitis—Erlotinib—kidney cancer	0.000124	0.000964	CcSEcCtD
Dapagliflozin—Hyponatraemia—Doxorubicin—kidney cancer	0.000123	0.000962	CcSEcCtD
Dapagliflozin—Headache—Erlotinib—kidney cancer	0.000123	0.000959	CcSEcCtD
Dapagliflozin—Constipation—Vincristine—kidney cancer	0.000123	0.000959	CcSEcCtD
Dapagliflozin—Pain in extremity—Doxorubicin—kidney cancer	0.000123	0.000958	CcSEcCtD
Dapagliflozin—Nausea—Vinblastine—kidney cancer	0.000121	0.000946	CcSEcCtD
Dapagliflozin—Nausea—Everolimus—kidney cancer	0.000121	0.000942	CcSEcCtD
Dapagliflozin—Hypertension—Paclitaxel—kidney cancer	0.000121	0.000942	CcSEcCtD
Dapagliflozin—Hypersensitivity—Dactinomycin—kidney cancer	0.000119	0.000924	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000118	0.000922	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000118	0.000918	CcSEcCtD
Dapagliflozin—Discomfort—Paclitaxel—kidney cancer	0.000118	0.000918	CcSEcCtD
Dapagliflozin—Dizziness—Sorafenib—kidney cancer	0.000117	0.000911	CcSEcCtD
Dapagliflozin—Constipation—Gemcitabine—kidney cancer	0.000117	0.000909	CcSEcCtD
Dapagliflozin—Nausea—Erlotinib—kidney cancer	0.000117	0.000909	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Doxorubicin—kidney cancer	0.000115	0.000898	CcSEcCtD
Dapagliflozin—Malnutrition—Capecitabine—kidney cancer	0.000115	0.000895	CcSEcCtD
Dapagliflozin—Dehydration—Doxorubicin—kidney cancer	0.000114	0.000891	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Paclitaxel—kidney cancer	0.000114	0.00089	CcSEcCtD
Dapagliflozin—Oedema—Paclitaxel—kidney cancer	0.000114	0.00089	CcSEcCtD
Dapagliflozin—Body temperature increased—Vincristine—kidney cancer	0.000114	0.000886	CcSEcCtD
Dapagliflozin—Infection—Paclitaxel—kidney cancer	0.000114	0.000884	CcSEcCtD
Dapagliflozin—Dizziness—Sunitinib—kidney cancer	0.000112	0.000876	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000112	0.000875	CcSEcCtD
Dapagliflozin—Rash—Sorafenib—kidney cancer	0.000111	0.000868	CcSEcCtD
Dapagliflozin—Dermatitis—Sorafenib—kidney cancer	0.000111	0.000868	CcSEcCtD
Dapagliflozin—Back pain—Capecitabine—kidney cancer	0.000111	0.000866	CcSEcCtD
Dapagliflozin—Skin disorder—Paclitaxel—kidney cancer	0.000111	0.000865	CcSEcCtD
Dapagliflozin—Headache—Sorafenib—kidney cancer	0.000111	0.000863	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Paclitaxel—kidney cancer	0.00011	0.000861	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Doxorubicin—kidney cancer	0.00011	0.000857	CcSEcCtD
Dapagliflozin—Body temperature increased—Gemcitabine—kidney cancer	0.000108	0.000841	CcSEcCtD
Dapagliflozin—Rash—Sunitinib—kidney cancer	0.000107	0.000836	CcSEcCtD
Dapagliflozin—Dermatitis—Sunitinib—kidney cancer	0.000107	0.000835	CcSEcCtD
Dapagliflozin—Hypotension—Paclitaxel—kidney cancer	0.000107	0.000832	CcSEcCtD
Dapagliflozin—Headache—Sunitinib—kidney cancer	0.000107	0.00083	CcSEcCtD
Dapagliflozin—Influenza—Doxorubicin—kidney cancer	0.000106	0.000828	CcSEcCtD
Dapagliflozin—Hypersensitivity—Vincristine—kidney cancer	0.000106	0.000826	CcSEcCtD
Dapagliflozin—Nausea—Sorafenib—kidney cancer	0.000105	0.000818	CcSEcCtD
Dapagliflozin—Angina pectoris—Doxorubicin—kidney cancer	0.000104	0.000807	CcSEcCtD
Dapagliflozin—Rash—Dactinomycin—kidney cancer	0.000102	0.000791	CcSEcCtD
Dapagliflozin—Nausea—Sunitinib—kidney cancer	0.000101	0.000787	CcSEcCtD
Dapagliflozin—Dysuria—Doxorubicin—kidney cancer	9.94e-05	0.000774	CcSEcCtD
Dapagliflozin—Hypertension—Capecitabine—kidney cancer	9.92e-05	0.000773	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Paclitaxel—kidney cancer	9.87e-05	0.000769	CcSEcCtD
Dapagliflozin—Pollakiuria—Doxorubicin—kidney cancer	9.82e-05	0.000765	CcSEcCtD
Dapagliflozin—Constipation—Paclitaxel—kidney cancer	9.77e-05	0.000761	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	9.72e-05	0.000757	CcSEcCtD
Dapagliflozin—Discomfort—Capecitabine—kidney cancer	9.67e-05	0.000753	CcSEcCtD
Dapagliflozin—Nausea—Dactinomycin—kidney cancer	9.57e-05	0.000745	CcSEcCtD
Dapagliflozin—Dizziness—Vincristine—kidney cancer	9.51e-05	0.000741	CcSEcCtD
Dapagliflozin—Infestation NOS—Doxorubicin—kidney cancer	9.48e-05	0.000738	CcSEcCtD
Dapagliflozin—Infestation—Doxorubicin—kidney cancer	9.48e-05	0.000738	CcSEcCtD
Dapagliflozin—Oedema—Capecitabine—kidney cancer	9.38e-05	0.000731	CcSEcCtD
Dapagliflozin—Renal failure—Doxorubicin—kidney cancer	9.32e-05	0.000726	CcSEcCtD
Dapagliflozin—Infection—Capecitabine—kidney cancer	9.32e-05	0.000726	CcSEcCtD
Dapagliflozin—Urinary tract infection—Doxorubicin—kidney cancer	9.21e-05	0.000718	CcSEcCtD
Dapagliflozin—Skin disorder—Capecitabine—kidney cancer	9.11e-05	0.00071	CcSEcCtD
Dapagliflozin—Urticaria—Paclitaxel—kidney cancer	9.08e-05	0.000707	CcSEcCtD
Dapagliflozin—Rash—Vincristine—kidney cancer	9.07e-05	0.000707	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Capecitabine—kidney cancer	9.07e-05	0.000706	CcSEcCtD
Dapagliflozin—Dermatitis—Vincristine—kidney cancer	9.06e-05	0.000706	CcSEcCtD
Dapagliflozin—Body temperature increased—Paclitaxel—kidney cancer	9.03e-05	0.000704	CcSEcCtD
Dapagliflozin—Headache—Vincristine—kidney cancer	9.01e-05	0.000702	CcSEcCtD
Dapagliflozin—Hypotension—Capecitabine—kidney cancer	8.76e-05	0.000683	CcSEcCtD
Dapagliflozin—Rash—Gemcitabine—kidney cancer	8.61e-05	0.00067	CcSEcCtD
Dapagliflozin—Dermatitis—Gemcitabine—kidney cancer	8.6e-05	0.00067	CcSEcCtD
Dapagliflozin—Headache—Gemcitabine—kidney cancer	8.55e-05	0.000666	CcSEcCtD
Dapagliflozin—Nausea—Vincristine—kidney cancer	8.55e-05	0.000666	CcSEcCtD
Dapagliflozin—Hypersensitivity—Paclitaxel—kidney cancer	8.42e-05	0.000656	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Doxorubicin—kidney cancer	8.4e-05	0.000655	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Doxorubicin—kidney cancer	8.36e-05	0.000651	CcSEcCtD
Dapagliflozin—Urethral disorder—Doxorubicin—kidney cancer	8.34e-05	0.00065	CcSEcCtD
Dapagliflozin—Nausea—Gemcitabine—kidney cancer	8.11e-05	0.000632	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Capecitabine—kidney cancer	8.1e-05	0.000631	CcSEcCtD
Dapagliflozin—Constipation—Capecitabine—kidney cancer	8.02e-05	0.000625	CcSEcCtD
Dapagliflozin—Dizziness—Paclitaxel—kidney cancer	7.56e-05	0.000589	CcSEcCtD
Dapagliflozin—Urticaria—Capecitabine—kidney cancer	7.45e-05	0.00058	CcSEcCtD
Dapagliflozin—Body temperature increased—Capecitabine—kidney cancer	7.41e-05	0.000578	CcSEcCtD
Dapagliflozin—Malnutrition—Doxorubicin—kidney cancer	7.41e-05	0.000577	CcSEcCtD
Dapagliflozin—Rash—Paclitaxel—kidney cancer	7.21e-05	0.000561	CcSEcCtD
Dapagliflozin—Dermatitis—Paclitaxel—kidney cancer	7.2e-05	0.000561	CcSEcCtD
Dapagliflozin—Back pain—Doxorubicin—kidney cancer	7.17e-05	0.000558	CcSEcCtD
Dapagliflozin—Headache—Paclitaxel—kidney cancer	7.16e-05	0.000558	CcSEcCtD
Dapagliflozin—Hypersensitivity—Capecitabine—kidney cancer	6.91e-05	0.000538	CcSEcCtD
Dapagliflozin—Nausea—Paclitaxel—kidney cancer	6.79e-05	0.000529	CcSEcCtD
Dapagliflozin—Hypertension—Doxorubicin—kidney cancer	6.4e-05	0.000498	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	6.26e-05	0.000488	CcSEcCtD
Dapagliflozin—Discomfort—Doxorubicin—kidney cancer	6.23e-05	0.000485	CcSEcCtD
Dapagliflozin—Dizziness—Capecitabine—kidney cancer	6.2e-05	0.000483	CcSEcCtD
Dapagliflozin—Oedema—Doxorubicin—kidney cancer	6.05e-05	0.000471	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Doxorubicin—kidney cancer	6.05e-05	0.000471	CcSEcCtD
Dapagliflozin—Infection—Doxorubicin—kidney cancer	6.01e-05	0.000468	CcSEcCtD
Dapagliflozin—Rash—Capecitabine—kidney cancer	5.91e-05	0.000461	CcSEcCtD
Dapagliflozin—Dermatitis—Capecitabine—kidney cancer	5.91e-05	0.00046	CcSEcCtD
Dapagliflozin—Headache—Capecitabine—kidney cancer	5.88e-05	0.000458	CcSEcCtD
Dapagliflozin—Skin disorder—Doxorubicin—kidney cancer	5.87e-05	0.000457	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Doxorubicin—kidney cancer	5.84e-05	0.000455	CcSEcCtD
Dapagliflozin—Hypotension—Doxorubicin—kidney cancer	5.65e-05	0.00044	CcSEcCtD
Dapagliflozin—Nausea—Capecitabine—kidney cancer	5.57e-05	0.000434	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Doxorubicin—kidney cancer	5.22e-05	0.000407	CcSEcCtD
Dapagliflozin—Constipation—Doxorubicin—kidney cancer	5.17e-05	0.000403	CcSEcCtD
Dapagliflozin—Urticaria—Doxorubicin—kidney cancer	4.8e-05	0.000374	CcSEcCtD
Dapagliflozin—Body temperature increased—Doxorubicin—kidney cancer	4.78e-05	0.000372	CcSEcCtD
Dapagliflozin—Hypersensitivity—Doxorubicin—kidney cancer	4.45e-05	0.000347	CcSEcCtD
Dapagliflozin—Dizziness—Doxorubicin—kidney cancer	4e-05	0.000311	CcSEcCtD
Dapagliflozin—Rash—Doxorubicin—kidney cancer	3.81e-05	0.000297	CcSEcCtD
Dapagliflozin—Dermatitis—Doxorubicin—kidney cancer	3.81e-05	0.000297	CcSEcCtD
Dapagliflozin—Headache—Doxorubicin—kidney cancer	3.79e-05	0.000295	CcSEcCtD
Dapagliflozin—Nausea—Doxorubicin—kidney cancer	3.59e-05	0.00028	CcSEcCtD
Dapagliflozin—CYP1A2—Metabolism—CCBL1—kidney cancer	9.91e-06	8.71e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CRABP1—kidney cancer	9.91e-06	8.71e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	9.87e-06	8.68e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	9.82e-06	8.64e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	9.65e-06	8.49e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ACY1—kidney cancer	9.56e-06	8.41e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—BCHE—kidney cancer	9.49e-06	8.35e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—FH—kidney cancer	9.42e-06	8.29e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—APRT—kidney cancer	9.42e-06	8.29e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GPC3—kidney cancer	9.4e-06	8.27e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—SLC5A5—kidney cancer	9.37e-06	8.25e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—APRT—kidney cancer	9.34e-06	8.22e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—FH—kidney cancer	9.34e-06	8.22e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GSTP1—kidney cancer	9.29e-06	8.17e-05	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PTEN—kidney cancer	9.22e-06	8.11e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ITPR2—kidney cancer	9.21e-06	8.1e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	9.18e-06	8.08e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CA2—kidney cancer	9.15e-06	8.05e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	9.14e-06	8.04e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	9.13e-06	8.03e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—SLC2A1—kidney cancer	9.05e-06	7.96e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	8.96e-06	7.88e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ALAD—kidney cancer	8.91e-06	7.84e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	8.87e-06	7.8e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GPC3—kidney cancer	8.86e-06	7.79e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ABCB1—kidney cancer	8.8e-06	7.74e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GPC3—kidney cancer	8.78e-06	7.73e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	8.78e-06	7.73e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	8.72e-06	7.67e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ST3GAL2—kidney cancer	8.7e-06	7.65e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	8.7e-06	7.65e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CA9—kidney cancer	8.68e-06	7.63e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	8.63e-06	7.6e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CA2—kidney cancer	8.62e-06	7.58e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPAT—kidney cancer	8.59e-06	7.55e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GLIPR1—kidney cancer	8.59e-06	7.55e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CA2—kidney cancer	8.55e-06	7.52e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GSTM1—kidney cancer	8.54e-06	7.51e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ALDH1A1—kidney cancer	8.5e-06	7.48e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	8.48e-06	7.46e-05	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PIK3CA—kidney cancer	8.42e-06	7.41e-05	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PIK3CA—kidney cancer	8.42e-06	7.41e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	8.42e-06	7.4e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ALAD—kidney cancer	8.4e-06	7.39e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GSTT1—kidney cancer	8.4e-06	7.39e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ACHE—kidney cancer	8.4e-06	7.39e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	8.39e-06	7.38e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ALAD—kidney cancer	8.33e-06	7.33e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ST3GAL2—kidney cancer	8.2e-06	7.21e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PGK1—kidney cancer	8.15e-06	7.17e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SLC5A3—kidney cancer	8.15e-06	7.17e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PDHB—kidney cancer	8.13e-06	7.15e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ST3GAL2—kidney cancer	8.13e-06	7.15e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—POMC—kidney cancer	8.11e-06	7.13e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CYP1A1—kidney cancer	8.09e-06	7.12e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ALDH1A1—kidney cancer	8.01e-06	7.05e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—LDHB—kidney cancer	8e-06	7.03e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—APRT—kidney cancer	7.98e-06	7.02e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—FH—kidney cancer	7.98e-06	7.02e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—SCARB1—kidney cancer	7.95e-06	6.99e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ALDH1A1—kidney cancer	7.94e-06	6.99e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTGS1—kidney cancer	7.87e-06	6.92e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	7.8e-06	6.86e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PSMD7—kidney cancer	7.72e-06	6.79e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SLC5A3—kidney cancer	7.68e-06	6.76e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PGK1—kidney cancer	7.68e-06	6.76e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	7.66e-06	6.74e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CCBL1—kidney cancer	7.64e-06	6.72e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PGK1—kidney cancer	7.62e-06	6.7e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SLC5A3—kidney cancer	7.62e-06	6.7e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	7.6e-06	6.69e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GSTP1—kidney cancer	7.55e-06	6.64e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—LDHB—kidney cancer	7.53e-06	6.63e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GPC3—kidney cancer	7.51e-06	6.6e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—LDHB—kidney cancer	7.47e-06	6.57e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CRABP1—kidney cancer	7.38e-06	6.49e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—BCHE—kidney cancer	7.32e-06	6.44e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CA2—kidney cancer	7.3e-06	6.42e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—SLC5A5—kidney cancer	7.23e-06	6.36e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	7.19e-06	6.33e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ABCB1—kidney cancer	7.15e-06	6.29e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALAD—kidney cancer	7.12e-06	6.26e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	6.99e-06	6.15e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—SLC2A1—kidney cancer	6.98e-06	6.14e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ST3GAL2—kidney cancer	6.95e-06	6.11e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GSTM1—kidney cancer	6.94e-06	6.1e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CA9—kidney cancer	6.93e-06	6.1e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ITPR2—kidney cancer	6.86e-06	6.04e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	6.84e-06	6.02e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALDH1A1—kidney cancer	6.79e-06	5.97e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GLIPR1—kidney cancer	6.63e-06	5.83e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPAT—kidney cancer	6.63e-06	5.83e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CYP1A1—kidney cancer	6.58e-06	5.79e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CA9—kidney cancer	6.53e-06	5.75e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PGK1—kidney cancer	6.51e-06	5.73e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC5A3—kidney cancer	6.51e-06	5.73e-05	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PIK3CA—kidney cancer	6.5e-06	5.72e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CA9—kidney cancer	6.48e-06	5.7e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	6.46e-06	5.68e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—LDHB—kidney cancer	6.38e-06	5.61e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	6.33e-06	5.57e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—POMC—kidney cancer	6.32e-06	5.56e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTT1—kidney cancer	6.26e-06	5.5e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ACHE—kidney cancer	6.26e-06	5.5e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—FH—kidney cancer	6.16e-06	5.42e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—APRT—kidney cancer	6.16e-06	5.42e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—POMC—kidney cancer	6.04e-06	5.31e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	5.94e-06	5.22e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—SCARB1—kidney cancer	5.92e-06	5.21e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CRABP1—kidney cancer	5.89e-06	5.19e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTGS1—kidney cancer	5.86e-06	5.16e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GSTP1—kidney cancer	5.82e-06	5.12e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GPC3—kidney cancer	5.79e-06	5.1e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PSMD7—kidney cancer	5.75e-06	5.06e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	5.74e-06	5.05e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CA2—kidney cancer	5.64e-06	4.96e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CRABP1—kidney cancer	5.55e-06	4.89e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CA9—kidney cancer	5.53e-06	4.87e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ABCB1—kidney cancer	5.51e-06	4.85e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CRABP1—kidney cancer	5.51e-06	4.84e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALAD—kidney cancer	5.49e-06	4.83e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ITPR2—kidney cancer	5.48e-06	4.82e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—BCHE—kidney cancer	5.45e-06	4.79e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	5.41e-06	4.76e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	5.4e-06	4.75e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—SLC5A5—kidney cancer	5.38e-06	4.74e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ST3GAL2—kidney cancer	5.36e-06	4.72e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GSTM1—kidney cancer	5.35e-06	4.71e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALDH1A1—kidney cancer	5.24e-06	4.61e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—SLC2A1—kidney cancer	5.2e-06	4.57e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ITPR2—kidney cancer	5.16e-06	4.54e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ITPR2—kidney cancer	5.12e-06	4.5e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYP1A1—kidney cancer	5.07e-06	4.46e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	5.04e-06	4.44e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PGK1—kidney cancer	5.02e-06	4.42e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC5A3—kidney cancer	5.02e-06	4.42e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTT1—kidney cancer	5e-06	4.4e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ACHE—kidney cancer	5e-06	4.4e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—LDHB—kidney cancer	4.93e-06	4.33e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—POMC—kidney cancer	4.9e-06	4.31e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTGS2—kidney cancer	4.81e-06	4.23e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SCARB1—kidney cancer	4.73e-06	4.16e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	4.72e-06	4.15e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ACHE—kidney cancer	4.71e-06	4.14e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTT1—kidney cancer	4.71e-06	4.14e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CRABP1—kidney cancer	4.71e-06	4.14e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTGS1—kidney cancer	4.68e-06	4.12e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ACHE—kidney cancer	4.67e-06	4.11e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTT1—kidney cancer	4.67e-06	4.11e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PSMD7—kidney cancer	4.59e-06	4.04e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SCARB1—kidney cancer	4.46e-06	3.92e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SCARB1—kidney cancer	4.42e-06	3.89e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTGS1—kidney cancer	4.41e-06	3.88e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.4e-06	3.87e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ITPR2—kidney cancer	4.37e-06	3.85e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTGS1—kidney cancer	4.37e-06	3.85e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—BCHE—kidney cancer	4.35e-06	3.83e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTP1—kidney cancer	4.34e-06	3.81e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PSMD7—kidney cancer	4.33e-06	3.81e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SLC5A5—kidney cancer	4.3e-06	3.78e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PSMD7—kidney cancer	4.29e-06	3.77e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CA9—kidney cancer	4.27e-06	3.76e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTEN—kidney cancer	4.2e-06	3.69e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SLC2A1—kidney cancer	4.15e-06	3.65e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ABCB1—kidney cancer	4.11e-06	3.61e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—BCHE—kidney cancer	4.1e-06	3.61e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—BCHE—kidney cancer	4.07e-06	3.58e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SLC5A5—kidney cancer	4.05e-06	3.56e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	4.03e-06	3.55e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SLC5A5—kidney cancer	4.02e-06	3.53e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTT1—kidney cancer	3.99e-06	3.51e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ACHE—kidney cancer	3.99e-06	3.51e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTM1—kidney cancer	3.99e-06	3.51e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	3.96e-06	3.48e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SLC2A1—kidney cancer	3.91e-06	3.44e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTGS2—kidney cancer	3.91e-06	3.44e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SLC2A1—kidney cancer	3.88e-06	3.41e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—POMC—kidney cancer	3.78e-06	3.33e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SCARB1—kidney cancer	3.78e-06	3.32e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.76e-06	3.31e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTGS1—kidney cancer	3.74e-06	3.29e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PSMD7—kidney cancer	3.67e-06	3.22e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CRABP1—kidney cancer	3.63e-06	3.19e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—BCHE—kidney cancer	3.48e-06	3.06e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTP1—kidney cancer	3.46e-06	3.05e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC5A5—kidney cancer	3.43e-06	3.02e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTEN—kidney cancer	3.41e-06	3e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ITPR2—kidney cancer	3.38e-06	2.97e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC2A1—kidney cancer	3.32e-06	2.92e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.28e-06	2.89e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTP1—kidney cancer	3.26e-06	2.87e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTP1—kidney cancer	3.24e-06	2.85e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.22e-06	2.83e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTM1—kidney cancer	3.18e-06	2.8e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.1e-06	2.73e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ABCB1—kidney cancer	3.09e-06	2.72e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTT1—kidney cancer	3.08e-06	2.71e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ACHE—kidney cancer	3.08e-06	2.71e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ABCB1—kidney cancer	3.06e-06	2.69e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP1A1—kidney cancer	3.02e-06	2.65e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTGS2—kidney cancer	3.02e-06	2.65e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTM1—kidney cancer	3e-06	2.64e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTM1—kidney cancer	2.97e-06	2.62e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CA—kidney cancer	2.96e-06	2.61e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SCARB1—kidney cancer	2.91e-06	2.56e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTGS1—kidney cancer	2.89e-06	2.54e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP1A1—kidney cancer	2.84e-06	2.5e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PSMD7—kidney cancer	2.83e-06	2.49e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP1A1—kidney cancer	2.82e-06	2.48e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—POMC—kidney cancer	2.82e-06	2.48e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.81e-06	2.47e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTP1—kidney cancer	2.77e-06	2.43e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—BCHE—kidney cancer	2.68e-06	2.36e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC5A5—kidney cancer	2.65e-06	2.33e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTEN—kidney cancer	2.63e-06	2.31e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ABCB1—kidney cancer	2.62e-06	2.3e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC2A1—kidney cancer	2.56e-06	2.25e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTM1—kidney cancer	2.54e-06	2.24e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP1A1—kidney cancer	2.41e-06	2.12e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CA—kidney cancer	2.41e-06	2.12e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.32e-06	2.04e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—POMC—kidney cancer	2.25e-06	1.98e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTGS2—kidney cancer	2.25e-06	1.98e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTP1—kidney cancer	2.13e-06	1.88e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—POMC—kidney cancer	2.12e-06	1.86e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—POMC—kidney cancer	2.1e-06	1.85e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ABCB1—kidney cancer	2.02e-06	1.78e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.98e-06	1.74e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTM1—kidney cancer	1.96e-06	1.73e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTEN—kidney cancer	1.96e-06	1.72e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.86e-06	1.64e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CA—kidney cancer	1.86e-06	1.63e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—POMC—kidney cancer	1.8e-06	1.58e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTGS2—kidney cancer	1.79e-06	1.58e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTGS2—kidney cancer	1.69e-06	1.49e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTGS2—kidney cancer	1.68e-06	1.47e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTEN—kidney cancer	1.56e-06	1.38e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTEN—kidney cancer	1.47e-06	1.3e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTEN—kidney cancer	1.46e-06	1.29e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTGS2—kidney cancer	1.43e-06	1.26e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—POMC—kidney cancer	1.39e-06	1.22e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CA—kidney cancer	1.38e-06	1.22e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTEN—kidney cancer	1.25e-06	1.1e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTGS2—kidney cancer	1.11e-06	9.73e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CA—kidney cancer	1.1e-06	9.71e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.04e-06	9.15e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CA—kidney cancer	1.03e-06	9.07e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTEN—kidney cancer	9.64e-07	8.48e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CA—kidney cancer	8.81e-07	7.75e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CA—kidney cancer	6.8e-07	5.98e-06	CbGpPWpGaD
